London: The UK drug regulator has said that the Corona Virus anti-AstraZeneca vaccine has wide benefits, but in rare cases of blood clot formation for 30 years. Second vaccines will be offered to younger people.
The country’s ‘Medicines and Healthcare Products Regulatory Agency’ (MHRA) said on Wednesday that as long as it is studying the association between the AstraZeneca vaccine and rare blood clots, people in the respective age groups should be referred to the Pfizer and Moderna company. Vaccines should be applied.
Head of MHRA, Doctor June Raine, said that the benefits of the AstraZeneca vaccine are greater in most people than the risks. The decision was announced shortly after the European Union’s drug regulator stated that it had detected a “possible contact” between AstraZeneca’s vaccine and rare blood clots.
